Jonathan Alicea

New data shows ischemic heart disease mortality decline has decelerated in recent years—while other heart disease subtypes have reversed course.

J. John Mann, MD, gives a brief overview of where we are now in treatment of major depressive disorder.

Valoctocogene roxaparvovec would be the first ever approved gene therapy to treat patients with hemophilia A.

Recent surveys reveal that 40.9% of 5470 respondents are suffering from adverse mental or behavioral health conditions related to the pandemic.

Over a nine-year period, the observed incidence of ROP in infants with very low birth weight was 317.14 per 1000 newborns.

Data suggests treatment with the palliative opioid does not affect PCO2 levels, suggesting it is safe in patients with moderate to severe COPD.

A single nucleotide polymorphism is associated with severe and proliferative retinopathy risk reduction by 42% and 63%, respectively.

According to new findings, low Glx response is associated with increase in clinical improvements in at-need patients.

Treatment with the PCSK9 Inhibitor did not increase risk of safety events, including new-onset diabetes.

Patients with IPF and multiple comorbidities experienced similar effects from nintedanib to those with few or no comorbidities.

MagVenture TMS Therapy can be used as adjunctive therapy to other OCD treatments.

In a cross-sectional study among CAD patients, investigators found that 30.3% of heart team treatment recommendations diverged from original consultation.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.

A new study has great implications for equitable access to primary care for older adults during the pandemic.